- Home
- OGI vs FHTX Comparison
OGI vs FHTX Comparison
Compare OGI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- FHTX
- Stock Information
- Founded
- OGI 2013
- FHTX 2015
- Country
- OGI Canada
- FHTX United States
- Employees
- OGI N/A
- FHTX N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- OGI Health Care
- FHTX Health Care
- Exchange
- OGI Nasdaq
- FHTX Nasdaq
- Market Cap
- OGI 200.6M
- FHTX 237.4M
- IPO Year
- OGI N/A
- FHTX 2020
- Fundamental
- Price
- OGI $1.55
- FHTX $4.31
- Analyst Decision
- OGI
- FHTX Strong Buy
- Analyst Count
- OGI 0
- FHTX 5
- Target Price
- OGI N/A
- FHTX $13.80
- AVG Volume (30 Days)
- OGI 710.4K
- FHTX 170.9K
- Earning Date
- OGI 02-11-2025
- FHTX 03-06-2025
- Dividend Yield
- OGI N/A
- FHTX N/A
- EPS Growth
- OGI N/A
- FHTX N/A
- EPS
- OGI N/A
- FHTX N/A
- Revenue
- OGI $118,317,480.00
- FHTX $25,515,000.00
- Revenue This Year
- OGI $57.65
- FHTX N/A
- Revenue Next Year
- OGI $10.93
- FHTX $7.37
- P/E Ratio
- OGI N/A
- FHTX N/A
- Revenue Growth
- OGI 0.69
- FHTX N/A
- 52 Week Low
- OGI $1.31
- FHTX $2.70
- 52 Week High
- OGI $2.91
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- OGI 46.68
- FHTX 31.80
- Support Level
- OGI $1.51
- FHTX $4.13
- Resistance Level
- OGI $1.77
- FHTX $4.47
- Average True Range (ATR)
- OGI 0.08
- FHTX 0.36
- MACD
- OGI -0.01
- FHTX 0.06
- Stochastic Oscillator
- OGI 18.52
- FHTX 16.51
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.